SCHEMBL6832471

SCHEMBL6832471

Bc1cc(-c2ccn[nH]c2=O)cc(C(C)(C)C)c1OC

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 3/20 0.38
CYP3A4 P08684 3/20 0.36
BRD4 O60885 2/20 0.34
ERBB2 P04626 2/20 0.34
PTGS1 P23219 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32
HPGD P15428 1/20 0.32
MAPK1 P28482 1/20 0.32
HSD17B10 Q99714 1/20 0.32
EGFR P00533 1/20 0.31
ADORA2A P29274 1/20 0.31
ADORA1 P30542 1/20 0.31
SCN4A P35499 1/20 0.31
ADRA2A P08913 1/20 0.30
ADRA2C P18825 1/20 0.30
ADRA1D P25100 1/20 0.30
ADRA1A P35348 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6766113 0.86 PTGS2 (0.37) PTGS2CYP3A4BRD4ERBB2PTGS1
SCHEMBL6765715 0.86 ERBB2 (0.44) PTGS2CYP3A4BRD4ERBB2PTGS1
SCHEMBL2491302 0.79 RARA (0.43) CYP3A4ERBB2NPC1RAB9AKDM4E
SCHEMBL2490531 0.79 CYP3A4 (0.54) PTGS2CYP3A4ERBB2EGFRADORA2A
SCHEMBL2490533 0.79 CYP3A4 (0.54) PTGS2CYP3A4ERBB2EGFRADORA2A
SCHEMBL2492954 0.77 IKBKB (0.40) CYP3A4ERBB2KDM4EEGFRADORA2A
SCHEMBL6832451 0.77 CYP3A4 (0.52) PTGS2CYP3A4ERBB2
SCHEMBL6832515 0.76 CYP3A4 (0.43) PTGS2CYP3A4
SCHEMBL10134543 0.73 ITK (0.41) RAB9AKDM4EALDH1A1HPGDGAA
SCHEMBL2489645 0.73 CYP3A4 (0.73) CYP3A4ERBB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178547-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-05-15 US disclosed
US-20100158860-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS STEINER SANDRA 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100158860-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS RFC1, RRP1B, RRBP1 PTGS2 4240/4885CYP3A4 978/4885BRD4 1073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.